Last reviewed · How we verify
HB-201 intravenous administration. — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HB-201 intravenous administration. (HB-201 intravenous administration.) — Hookipa Biotech GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HB-201 intravenous administration. TARGET | HB-201 intravenous administration. | Hookipa Biotech GmbH | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HB-201 intravenous administration. CI watch — RSS
- HB-201 intravenous administration. CI watch — Atom
- HB-201 intravenous administration. CI watch — JSON
- HB-201 intravenous administration. alone — RSS
Cite this brief
Drug Landscape (2026). HB-201 intravenous administration. — Competitive Intelligence Brief. https://druglandscape.com/ci/hb-201-intravenous-administration. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab